Christopher McNair, Co-Founder“We bridge that divide between well-served and underserved communities to make sure that everyone has access to the clinical diagnostics and testing that allows them to be proactive and not reactive in their pursuit and maintenance of optimal health,” says Christopher McNair, Co-Founder of Magnus Diagnostics Laboratories.
Established in 2016, Magnus offers a broad range of testing services, from primary care to drugs of abuse toxicology to therapeutic drug and clinical trials. The company’s diagnostic instruments are tailored to match the needs of each healthcare professional, allowing them to respond faster and with more clarity to patient health and clinical studies.
As a trusted ethical laboratory on a federal and state level, Magnus collects, tests, analyzes, and reports on a variety of sample types for assessment across a broad range of sectors. The company performs specialized testing for neurodegenerative diseases such as Alzheimer’s and dementia, as well as rare diseases and disorders. It also offers drug of abuse testing in urine toxicology and therapeutic drug level monitoring for clinics and physicians dealing with the patients in the opioid epidemic.
The company’s brilliance stems from its team of experts in the field, which enables Magnus to undertake tests in support of researchers’ efforts to identify cures for a variety of cancers and other chronic terminal conditions. Dr. Phil McCarthy, a subject matter expert, industry veteran in numerous areas of medicine, and a medical lawyer is on board. Magnus is incredibly proud to be able to work together with him and use his expertise in molecular diagnostics, personalized medicine, genomics, neurodegenerative diseases, and CRISPR-cas9 to drive their testing capabilities. “With CRISPR, we are trying to address the concerns associated with Parkinson’s disease and neuropathological alterations in Alzheimer’s disease,” says Dr. McCarthy.
With best-in-class testing solutions, Magnus can work beyond the U.S. promoting proficiency, certifications, qualifications, and licensing internationally and on a national scale. It’s client base spans the commercial and federal sectors and includes not just primary care providers, but direct-to-consumer and business-to-business. The company places equal emphasis on quality assurance with its Magnus Detect initiative, a program aimed at expanding access to high-quality levels of testing, nationally and globally.
In pursuit of resolving all types of health disparities and outcomes, Magnus positions itself in the marketplace by embracing cutting-edge scientific methodologies, one of which is CRISPR-cas9. The company uses it for neurodegenerative diseases, dementia, Parkinson’s, and Alzheimer’s disease, and to study how these diseases affect people throughout their lives. The advantage Magnus brings to the table is the competency to use CRISPR to augment treatment for these conditions.
We bridge that divide between well-served and underserved communities to make sure that everyone has access to the clinical diagnostics and testing that allows them to be proactive and not reactive in their pursuit and maintenance of optimal health
One of its founding principles is ethical testing. From integration to workflows, Magnus ensures that everything is interoperable, sustainable, and future-proof, and that they will never sacrifice ethics. “At Magnus, we go above and beyond to deliver accurate, ethical, and timely testing that gives both our clients and their patients peace of mind,” affirms McNair.
Advancements Series to Explore Innovations in Diagnostics and Laboratory Technologies
Wednesday, April 17, 2024
Discover how advances in laboratory technologies are enabling clearer insights into patient health.
JUPITER, Fla - An upcoming segment of Advancements with Ted Danson will focus on developments in research, testing, and treatments for a wide range of cancers and chronic terminal illnesses.
With a look at Magnus Diagnostics Laboratories, Inc. (Magnus), audiences will learn how its testing practices and technologies equip healthcare providers with the latest in reporting and tracking capabilities that are currently available today. Viewers will see how Magnus provides tailored solutions to meet the needs of every healthcare provider, so they can respond faster, with clearer insights, into the health status of patients and clinical trials.
The show will explore how Magnus collects, tests, analyzes, and reports multiple sample types for review across a wide spectrum of industries. From routine primary care doctor level testing to high complexity molecular quantitation testing, spectators will discover how Magnus conducts specialized testing for rare diseases, disorders, and neuro-degenerative conditions like Alzheimer's and dementia.
"We look forward to sharing how we are ethically transforming cross sector pre-clinical research to clinical patient care," said Chris McNair, Co-Founder, Magnus Diagnostics.
In addition, the segment will highlight how Magnus strives to provide excellence across its specialties, which include drugs of abuse toxicology testing, research and development testing, primary care patient testing, and therapeutic drug level monitoring contracts.
"We look forward to sharing how developments in science and technology are supporting the search for new treatments," said Richard Lubin, senior producer for the Advancements series.
